ArticleTranslational lung cancer research2025
Spectral dual-layer detector CT-based radiomics-deep learning for predicting pathological aggressiveness of stage I lung adenocarcinoma: discrimination of precursor glandular lesions and invasive adenocarcinomas.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- Quantitative parameters of dual-layer spectral CT for differentiating metastatic and non-metastatic lymph nodes in colorectal cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Application of dual-energy computed tomography combined with radiomics in the clinical diagnosis of lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Advantages of integrating artificial intelligence and spectral CT for lung nodule classification and prognostic judgment: a narrative review.Journal of thoracic disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate diagnosis of early-stage lung adenocarcinoma (LA) subtypes is crucial for optimal patient management. Radiomics extract features from medical images reflect underlying biological information, while effective atomic number (Zeff) from new-generation spectral dual-layer detector computed tomography (SDCT) reflects tissue composition. This study evaluated the utility of SDCT-Zeff-based radiomics, deep learning (DL), and clinical features to differentiate between ground-glass nodule (GGN)-featured precursor glandular lesions (PGLs) and adenocarcinomas. Methods: Patients diagnosed with GGN who underwent preoperative contrast-enhanced SDCT at two medical centers were prospectively enrolled between January 2022 and April 2024. Center 1 (Shengjing Hospital of China Medical University; n=582) served as the training cohort, while Center 2 (Shengjing Hospital, Huaxiang Branch; n=210) served as the external validation cohort. SDCT-Zeff delineated the region of interest (ROI) for radiomics feature extraction. A pre-trained ResNet50 model was used for DL feature extraction. Features were fused, screened, and integrated with various machine learning algorithms and clinical features to construct a clinical-based DL radiomics (DLR) signature nomogram, which was externally validated. Model performance was assessed regarding identification, calibration, and clinical utility. Results: A total of 792 GGNs were analyzed, classified as glandular precursor lesions (n=296) and adenocarcinomas (n=496). Zeff was inversely correlated with invasiveness. Three features were obtained: clinical, radiomics, and DL. LightGBM was identified as the best-performing model. The area under the curves (AUCs) of DLR in the training and test sets were 0.974 [95% confidence interval (CI): 0.963-0.983] and 0.827 (95% CI: 0.770-0.884), outperforming radiomics (AUC =0.897 and 0.765), and DL (AUC =0.929 and 0.758). The nomogram coupling clinical features [Zeff_a, electron density (ED)_a, and tumor abnormal protein (TAP)] showed the best predictive ability, with AUCs of 0.983 (95% CI: 0.974-0.990) and 0.833 (95% CI: 0.779-0.885) in the training and test sets. The calibration curve indicated strong agreement between predicted and observed outcomes in both cohorts. Decision curve analysis (DCA) revealed that this nomogram offers significant clinical benefits, with a threshold probability range surpassing other models. Conclusions: The coupled nomogram integrating SDCT-Zeff DLR with clinical features demonstrated improved predictive performance and was particularly effective in detecting GGN-featured glandular precursor lesions and adenocarcinomas. It provides a foundation for managing GGNs and offers valuable insights for preoperative evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.